Company / Shareholders' Equity
Neurocrine Biosciences Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$3.3B
FY2025
5-year range
$1.1B / $3.3B
FY2021-FY2025
Trend
+25.6%
vs FY2024
Sector context
#23 of 213
Health Care
What the data says
Neurocrine Biosciences's shareholders' equity of $3.3B is higher than 89% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 3 consecutive years, from $1.1B in FY2022 to $3.3B in FY2025.
Based on SEC 10-K filings.
$3.3B in FY2025 with a 5-year CAGR of +23.6%. Top quartile in the Health Care sector.
Improved from $2.2B to $3.3B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +42.4%
- 5-Year CAGR
- +23.6%
- 10-Year CAGR
- -
Sector benchmark
+27.7% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +23.6%, indicating consistent growth.
- In FY2025, shareholders' equity increased 25.6% year-over-year.
- Ranks #23 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.3B | +25.6% |
| FY2024 | $2.6B | +16.0% |
| FY2023 | $2.2B | +98.2% |
| FY2022 | $1.1B | -18.0% |
| FY2021 | $1.4B | +22.0% |
| FY2020 | $1.1B | +76.8% |
| FY2019 | $636.9M | +32.5% |
| FY2018 | $480.8M | +29.2% |
| FY2017 | $372.2M | +18.2% |
| FY2016 | $314.9M | -25.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026